June 16, 2025Clarametyx Biosciences Announces Positive Interim Analysis in Phase 2a Study Evaluating CMTX-101 for Infections Associated with Cystic FibrosisRead More May 2, 2025CincyTech Invests in Clarametyx to Advance Breakthrough Anti-Biofilm Therapies for Chronic Respiratory DiseaseRead More January 28, 2025Clarametyx Biosciences Announces Investment by Kineticos AMR Accelerator FundRead More January 7, 2025Clarametyx Biosciences Awarded a Multi-Phased Agreement with CARB-X to Accelerate Anti-Biofilm Vaccine to Prevent Bacterial InfectionsRead More November 19, 2024Clarametyx Bioscience Recognized as “Infectious Disease Innovation of the Year” In 2024 BioTech Breakthrough AwardsRead More October 17, 2024Clarametyx Biosciences Announces Progress on Study of Antibody Therapy CMTX-101 For Infections Associated With Cystic FibrosisRead More October 9, 2024Clarametyx to Present on Its Anti-Biofilm Technology Platform During Antimicrobial Pipeline Session At IDWeek 2024Read More May 28, 2024Clarametyx Biosciences Appoints Renowned Experts to Augment Strategic and Scientific Advisory BoardsRead More April 22, 2024Clarametyx Biosciences Expands Team Expertise to Accelerate Pipeline MomentumRead More
